The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Current unmet needs in PV & ET
Ronald Hoffman, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, outlines the most pressing unmet needs in patients with polycythemia vera (PV) and essential thrombocythemia (ET), which include better maintenance of hematocrit levels in PV, and improving our understanding of the biology of thrombosis in patients with ET to prevent the occurrence of thrombotic episodes and prevent progression to myelofibrosis (MF) and myeloproliferative neoplasm (MPN)-blast phase (BP). Nevertheless, this requires conducting long studies with a large number of patients that are difficult to sponsor. This interview took place virtually.
